

# 2025 Earnings Results

---

March 31<sup>st</sup>, 2026

(<https://www.oriongroup.co.kr/invest/finance/84>)

**This document has been prepared based on the consolidated financial statements for the 2025 fiscal year, which have undergone an external audit, for the convenience of our shareholders and investors.**

**Certain information contained in this document includes forward-looking statements regarding the future financial position and business outlook of the Company.**

**Please be advised that these forward-looking statements involve known and unknown risks, uncertainties, and other factors—such as changes in the market environment and the Company’s strategic direction—which may cause actual results to differ materially from those expressed or implied herein.**

**Under no circumstances shall this document serve as legal evidence for any investment outcomes or decisions made by investors.**

- 01**      **Financial Results Summary**
  - 2025 Consolidated Earnings Summary
  - 2025 Performance by Business Segment
  
- 02**      **Business Segment**
  - Public and Private Company Earnings
  
- 03**      **Shareholder Returns**
  - Dividend Status and Policy
  
- 04**      **Appendix**
  - Corporate Structure
  - Summary Financial Statements

# Financial Results Summary

## 2025 Financial Results Summary

(unit: 100mil KRW, %)

	FY2022	FY2023	FY2024	FY2025	YoY (vs 2024)
<b>Sales</b>	29,346 	29,538 	31,952 	33,931 	- Top-line growth led by Confectionery despite global slowdown
<b>Operating Profit (%)</b>	3,998 (13.6%) 	4,055 (13.7%) 	5,062 (15.8%) 	4,877 (14.4%) 	- Impacted by higher raw material costs and Showbox's YoY decline
<b>Net Income (%)</b>	3,236 (11.0%) 	2,904 (9.8%) 	4,795 (15.0%) 	3,378 (10.0%) 	- '24: One-time non-recurring items from LigaChem Bio acquisition
<b>EPS (KRW)</b>	1,712 	1,423 	2,670 	2,011 	-

# 2025 Performance by Business Segment

- Consolidate Operating Profit down due to raw material hikes & weak entertainment results, offset by Confectionery growth.
- Net income decreased by 29.6% (Base effect from '24 one-off gains from LigaChem Bio stake)

(unit: 100mil KRW, %, %p)


Classification	Sales			Operating Profit			Net Income		
	2024	2025	yoy %	2024	2025	yoy %	2024	2025	yoy %
Consolidate Results* (vs. Sales %)	31,952	<b>33,931</b>	<u>6.2%</u>	5,062 (15.8%)	<b>4,877</b> <b>(14.4%)</b>	<u>-3.7%</u> (-1.5%)	4,795 (15.0%)	<b>3,378</b> <b>(10.0%)</b>	<u>-29.6%</u> (-5.1%)
Confectionery (Orion Corp.)	31,043	<b>33,324</b>	7.3%	5,436 (17.5%)	<b>5,583</b> <b>(16.8%)</b>	2.7% (-0.8%)	5,332 (17.2%)	<b>3,906</b> <b>(11.7%)</b>	-26.7% (-5.5%)
Entertainment (Showbox Inc.)	931	<b>627</b>	-32.6%	245 (26.3%)	<b>-117</b> <b>(-18.6%)</b>	(turned to loss)	274 (29.5%)	<b>-150</b> <b>(-24.0%)</b>	(turned to loss)
Holdings	395	<b>760</b>	92.6%	264 (66.8%)	<b>628</b> <b>(82.6%)</b>	137.9% (15.7%p)	205 (51.8%)	<b>549</b> <b>(72.2%)</b>	168.4% (20.4%p)
Others (Mineral Water, Bio, etc)	154	<b>174</b>	13.0%	-56	<b>-106</b>	-	-123	<b>-136</b>	-

\* Reflecting consolidation adjustments (incl. intercompany eliminations)

- 01**      **Financial Results Summary**
  - 2025 Consolidated Earnings Summary
  - 2025 Performance by Business Segment
  
- 02**      **Business Segment**
  - Public and Private Company Earnings
  
- 03**      **Shareholder Returns**
  - Dividend Status and Policy
  
- 04**      **Appendix**
  - Corporate Structure
  - Summary Financial Statements


## Confectionery \_ Orion Corp.

(unit : 100mil KRW, %)



## Entertainment \_ Showbox Inc.

(unit : 100mil KRW)



## Business Results by Region

(unit : 100mil KRW, %)

Category		Korea	China	Vietnam	Russia	Total*
2025	Sales	11,458	13,207	5,381	3,394	33,324
	O.P	1,868	2,417	965	465	5,583
2024	Sales	10,976	12,701	5,145	2,305	31,043
	O.P	1,785	2,439	1,001	369	5,436
yoy %	Sales	4.4%	4.0%	4.6%	47.3%	7.3%
	O.P	4.7%	-0.9%	-3.6%	25.9%	2.7%

\*Reflects Indian/U.S. performance and consolidation adjustments

- ✓ Revenue growth across all entities despite global recession
- ✓ Sustained profit growth amid cost pressures from inflation

## 2025 Film Releases


(unit : mil, Box Office admissions)



'If only we'	'First Ride'	'Soju War'	'Lobby'	'The Soul bound'
(2.60)	(0.74)	(0.28)	(0.26)	(0.50)

- ✓ Operating loss (11.7 billion KRW) due to underperformance of major 2025 releases compared to the previous year
- '24 Key Releases: 'Exhuma' (11.91), 'Heartsping: Teenieping of Love' (1.24)

## Holdings \_ ORION Holdings (non-consolidated)



### Revenue Breakdown


(unit : 100mil KRW, %)

Category	2024	2025	yoy	yoy %
Rental	72	73	1	2.3%
Dividend	185	424	239	128.8%
Royalty	138	263	125	90.8%
Total	395	760	365	92.6%

✓ Increased dividend income from major subsidiaries

- Orion: KRW 36.9B (DPS KRW 1,250 → 2,500)
- Showbox: KRW 5.4B (DPS KRW 150)

## Lava Seawater \_ ORION Jeju Yongamsoo



### Revenue Breakdown

(unit : 100mil KRW, %)

Category	2024	2025	yoy	yoy %
Domestics	147	169	22	15.0%
(portion %)	(95.0%)	(96.9%)		
Exports	8	5	-2	-29.3%
(portion %)	(5.0%)	(3.1%)		
Total	154	174	20	12.8%




'Dr. You Lava Seawater'  
- 330ml, 530ml, 2L  
- label-free 530ml, 2L



'Immune Water'  
- 530ml  
- contains 5mg of 'Zinc'  
(59% of Daily value)

## Strategic Workflow




## Project Status

	<u>Entity</u>	<u>Progress Status</u>
<b>In-vitro Diagnostics (IVD)</b>	'Shandong Lukang Biotechnology Development Co., Ltd.' (Orion 65 : Lukang 35)	<ul style="list-style-type: none"> <li>• <b>Goal:</b> Commercialize 'Colorectal Cancer Diagnostic Kit' in China</li> <li>• <b>Status:</b> Marketing authorization applied with NMPA (China); currently awaiting approval</li> </ul>
<b>Tuberculosis (TB) Vaccine</b>	'Shanghai Anilam Biologics Co., Ltd'	<ul style="list-style-type: none"> <li>• <b>Goal:</b> Clinical approval, production, and sales of TB vaccine in China</li> <li>• <b>Status:</b> Preparing IND (Investigational New Drug) application for clinical trials in collaboration with Beijing Chest Hospital</li> </ul>
<b>Dental Care</b>	'Orion Biologics' (Orion 60 : Hysensbio 40)	<ul style="list-style-type: none"> <li>• <b>Goal:</b> Launch functional toothpaste (Global) &amp; develop treatment for dentin hypersensitivity (Korea)</li> <li>• <b>Status:</b> Secured global marketing permits for functional toothpaste ('25 Thailand, '26 Vietnam)</li> </ul>

- 01**      **Financial Results Summary**
  - 2025 Consolidated Earnings Summary
  - 2025 Performance by Business Segment
  
- 02**      **Business Segment**
  - Public and Private Company Earnings
  
- 03**      **Shareholder Returns**
  - Dividend Status and Policy
  
- 04**      **Appendix**
  - Corporate Structure
  - Summary Financial Statements

## Dividend Status

(unit : 100mil KRW, %)



## Three-Year Dividend Overview

(unit : 100mil KRW, %)

Category	(unit)	2023	2024	2025
Total Dividends	(KRW100mil)	451	481	662
Dividend per Share (DPS)	(KRW)	750	800	1,100
Dividend payout (consolidated)	(%)	52.7%	30.0%	54.7%
Net income (consolidated)	(KRW100mil)	856	1,606	1,210
Dividend Yield	(%)	4.9%	5.3%	4.9%

- ✓ '25 dividend increased by 37.5% yoy to KRW 1,100 per share  
→ Meets **'high-dividend criteria'**  
(separate taxation benefits applicable)

## Dividend Policy

Category	Description
Policy Direction	• Gradually expand total dividends and payout ratio within the range of distributable profits
Dividend Plan	• Pay annual dividend of <b>at least KRW 800</b> per share for the next three years ('25 ~ '27)
Dividend Type	• Cash Dividend (year-end)
Policy review	• Periodically reviewed considering earnings and investment requirements

## Shareholder Return Enhancement Plan ('26)

### Share Cancellation


- 2,488,770 shares (3.97%, book value KRW 11.6 bil)
- Scheduled for cancellation within '26

### Interim Dividend (Under Review)

- Establish legal basis in Articles of Incorporation (Approved at the March '26 AGM)

- 01**      **Financial Results Summary**
  - 2025 Consolidated Earnings Summary
  - 2025 Performance by Business Segment
  
- 02**      **Business Segment**
  - Public and Private Company Earnings
  
- 03**      **Shareholder Returns**
  - Dividend Status and Policy
  
- 04**      **Appendix**
  - Corporate Structure
  - Summary Financial Statements

# Appendix. Corporate Structure \_as of the end of 2025



# Appendix. Summary Financial Statements

## Consolidated P/L

(unit : 100mil KRW, %)

Category	2024 (portion%)	2025 (portion%)	yoy %
<b>Sales</b>	<b>31,952 (100.0%)</b>	<b>33,931 (100.0%)</b>	<b>6.2%</b>
Cost of goods sold	19,592 (61.3%)	21,665 (63.8%)	10.6%
Gross Profit	12,361 (38.7%)	12,267 (36.2%)	-0.8%
SG&A Expenses	7,298 (22.8%)	7,389 (21.8%)	1.2%
<b>Operating Profit</b>	<b>5,062 (15.8%)</b>	<b>4,877 (14.4%)</b>	<b>-3.7%</b>
Non-operating income&expenses	1,452 (4.5%)	178 (0.5%)	-87.8%
Profit before income tax	6,444 (20.2%)	4,780 (14.1%)	-25.8%
Income tax expense	1,649 (5.2%)	1,402 (4.1%)	-15.0%
<b>Net Income</b>	<b>4,795 (15.0%)</b>	<b>3,378 (10.0%)</b>	<b>-29.6%</b>
Attributable to Owners of the Parent	1,606 (5.0%)	1,210 (3.6%)	-24.7%
Non-controlling Interests	3,189 (10.0%)	2,168 (6.4%)	-32.0%

## Consolidated B/S

(unit : 100mil KRW, %)

Category	2024	2025	yoy %
Current Assets	17,356	19,779	14.0%
Cash&Cash equivalents	5,354	3,534	-34.0%
Accounts Receivable	1,812	1,849	2.0%
Inventory	3,183	3,242	1.9%
Others (ST Financial Deposits, etc.)	7,007	11,153	59.2%
Non-current Assets	41,976	42,055	0.2%
<b>Total Assets</b>	<b>59,332</b>	<b>61,834</b>	<b>4.2%</b>
Current Liability	7,072	7,075	0.0%
Non-current Liability	3,473	3,200	-7.8%
<b>Total Liabilities</b>	<b>10,545</b>	<b>10,275</b>	<b>-2.6%</b>
<b>Total Equity</b>	<b>48,787</b>	<b>51,559</b>	<b>5.7%</b>
Attributable to Owners of the Parent	23,708	24,636	3.9%